Drugs / NXC736
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05079425 | Sep 2021 → Nov 2022 | — | NEXTGEN Bioscience | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06104839 | Sep 2024 → Oct 2026 expected | alopecia areata | NEXTGEN Bioscience | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NXC-736 | “The purpose of this study is to evaluate the safety and efficacy of NXC-736 monotherapy in participants with severe alopecia areata (AA).” NCT06104839 ↗ |
| Route | Oral | “Oral administration” NCT05079425 ↗ |